TABLE 1.
Main characteristics of the recruited sample
| Variable | Value |
|---|---|
| Sociodemographic parameters | |
|
Age Gender Male Female Family history Scholarity Primary school Middle school High school University PhD/master |
44.36 ± 8.45 (43) 51 (52.0%) 47 (48.0%) 38 (38.8%) 3 (3.1%) 14 (14.3%) 35 (35.7%) 35 (35.7%) 11 (11.2%) |
| Disease | |
|
Plaque psoriasis Hidradenitis suppurativa Atopic dermatitis |
51 (52.0%) 25 (25.5%) 22 (22.4%) |
| Disease severity | |
|
Disease duration DLQI |
17.77 ± 7.19 (17) 12.3 ± 2.8 (12) |
| Psoriasis | |
|
PASI DAPSA |
2.9 ± 2.2 (3) 6.2 ± 3.7 (6) |
| Hidradenitis suppurativa | |
|
IHS4 ADDI |
7.8 ± 3.4 (8) 2.7 ± 0.8 (3) |
| Atopic dermatitis | |
| EASI | 7.8 ± 2.6 (8) |
| Biologic therapies | |
|
Adalimumab Dupilumab Etanercept Ustekinumab Ixekizumab Secukinumab Certolizumab |
36 (36.7%) 22 (22.4%) 13 (13.3%) 10 (10.2%) 8 (8.2%) 7 (7.1%) 2 (2.0%) |
Abbreviations: ADDI, Autoinflammatory Disease Damage Index; DAPSA, Disease Activity Index for PSoriatic Arthritis; DLQI, Dermatologic Life Quality Score; EASI, Eczema Area and Severity Index; IHS4, International Hidradenitis Suppurativa Severity Score System; PASI, Psoriasis Area Severity Index.